UBS Group AG lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 3.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,222,003 shares of the company’s stock after selling 45,483 shares during the period. UBS Group AG’s holdings in Sanofi were worth $59,218,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. CSM Advisors LLC bought a new position in Sanofi in the 3rd quarter valued at about $18,244,000. Caprock Group LLC purchased a new stake in Sanofi during the third quarter valued at about $1,347,000. Natixis Advisors LLC lifted its stake in Sanofi by 11.8% during the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock valued at $146,952,000 after buying an additional 327,569 shares in the last quarter. Assetmark Inc. lifted its stake in Sanofi by 25.0% during the third quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after buying an additional 71,356 shares in the last quarter. Finally, XY Capital Ltd purchased a new stake in Sanofi during the third quarter valued at about $1,603,000. Institutional investors own 14.03% of the company’s stock.
Wall Street Analyst Weigh In
SNY has been the subject of a number of analyst reports. Argus raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Monday, April 20th. Finally, UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $51.00.
Sanofi Trading Up 0.0%
NASDAQ:SNY opened at $43.36 on Wednesday. The stock’s 50 day moving average price is $46.32 and its 200 day moving average price is $47.85. Sanofi has a 52 week low of $43.10 and a 52 week high of $54.75. The company has a market capitalization of $105.76 billion, a P/E ratio of 12.11, a P/E/G ratio of 1.07 and a beta of 0.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be issued a $2.4225 dividend. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date is Monday, May 4th. Sanofi’s dividend payout ratio is currently 49.44%.
About Sanofi
Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
Featured Articles
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
